Harvard to integrate IP with Oxford Nanopore

10 August 2008

USA-based Harvard University's Office of Technology Development plans to integrate its discoveries in the nanopore area with technology in development by the UK's Oxford Nanopore Technologies.

Under the terms of this agreement, Oxford Nanopore has exclusive rights to develop and commercialize a number of nanopore technological breakthroughs developed in the laboratories of three investigators at Harvard and their collaborators at the University of California Santa Cruz and the National Institute of Standards and Technology, an agency of the US Department of Commerce.

According to the firms, these academics have pioneered the research of DNA translocation through nanopores and the potential for DNA sequencing using this method.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight